Crossmark

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults

Crossref DOI link: https://doi.org/10.1007/s13555-022-00744-8

Published Online: 2022-06-06

Published Print: 2022-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teng, Lida https://orcid.org/0000-0001-5879-9060
Mizukami, Akiko https://orcid.org/0000-0002-9507-199X
Ng, Cheryl https://orcid.org/0000-0002-1707-2305
Giannelos, Nikolaos

Curran, Desmond https://orcid.org/0000-0002-7423-0111
Sato, Tomohide https://orcid.org/0000-0002-5678-089X
Lee, Christa https://orcid.org/0000-0002-2220-187X
Matsuki, Taizo https://orcid.org/0000-0002-0591-4261
Funding

Funding for this research was provided by:

GlaxoSmithKline Biologicals SA
License Information

Text and Data Mining valid from 2022-06-01

Version of Record valid from 2022-06-06
More Information

Article History

Received: 24 February 2022

Accepted: 6 May 2022

First Online: 6 June 2022